Trials / Completed
CompletedNCT05480670
Treatment Benefits of Berberine Supplementation for Women With PCOS
Effect of Berberine Supplementation on Metabolic and Hormonal Features in Women With Polycystic Ovary Syndrome (PCOS)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Ayub Teaching Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
Berberine is a plant alkaloid, reportedly possesses a wide range of pharmacological activities, including anti-obesity and anti-dyslipidemia. Berberine is an effective insulin sensitizer and has a comparable activity to MET in reducing IR. A large body of evidence suggest that Berberine dietary supplementation helps in improvement of symptoms associated with Polycystic Ovary Syndrome (PCOS). The purpose of this study is to investigate the treatment benefits of Berberine in women with PCOS.
Detailed description
Berberine (BBR) is an isoquinoline derivative alkaloid that occurs in several plants including Oregon grape, barberry, tree turmeric, goldenseal, yellowroot, Amur corktree, Chinese goldthread, prickly poppy and Californian poppy. Berberine supplementation has been suggested to improve the symptoms associated with PCOS. Berberine; Reduces Insulin Resistance Lowers Blood Sugar Levels Aids in Weight Loss Improves Cholesterol Levels Regulates Menstrual Cycles Reduces Inflammation Helps Restore Hormonal Balance Improves Fertility Helps Combat Depression Helps Fight Fatty Liver Disease Improves Body Composition The present RCT is aimed to investigate the effect of Berberine on these symptoms associated with PCOS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Berberine | 550 mg Berberine supplement BDS for 3-months + changes in diet/life style. |
Timeline
- Start date
- 2022-11-01
- Primary completion
- 2023-03-31
- Completion
- 2023-04-15
- First posted
- 2022-07-29
- Last updated
- 2023-05-18
Locations
1 site across 1 country: Pakistan
Source: ClinicalTrials.gov record NCT05480670. Inclusion in this directory is not an endorsement.